Mineralys Therapeutics Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)

Mineralys Therapeutics (MLYS) granted inducement equity awards to two new non-executive employees effective September 8, 2026, under its 2025 Employment Inducement Incentive Award Plan.

Rhea-AI Summary

Mineralys Therapeutics (MLYS) granted inducement equity awards to two new non-executive employees effective September 8, 2026, under its 2025 Employment Inducement Incentive Award Plan.

The grants include stock options covering an aggregate of 29,760 shares and restricted stock units (RSUs) covering an aggregate of 22,320 shares of common stock. The options vest over four years, with 25% vesting on the first anniversary of the September 8, 2026 vesting commencement date and the remaining 75% vesting in equal monthly installments over the following three years, subject to continued service. The RSUs vest over four years, with 25% of the shares vesting on each of the first four anniversaries of the same vesting commencement date, subject to continued service and in accordance with Nasdaq Listing Rule 5635(c)(4).

Key Figures

Stock options: 29,760 shares Restricted stock units: 22,320 shares Recipients: Two employees +4 more

Stock options

29,760 shares

Inducement awards to two new non-executive employees

Restricted stock units

22,320 shares

Inducement awards to two new non-executive employees

Recipients

Two employees

New non-executive employees

Option vesting period

Four years

Subject to continued service

Initial option vesting

25%

On the first anniversary of the September 8, 2026 vesting commencement date

Monthly option vesting

1/48th

Following each one-month period after the first anniversary

RSU vesting

25% annually

On each of the first four anniversaries of September 8, 2026

Historical Context

2 past events · Latest: Aug 13

2 events

1. Aug 13

   Inducement awards

   24h Move

   -1.6%

   Awards granted under the same employment inducement incentive plan

2. Jul 27

   Inducement awards

   24h Move

   -1.0%

   Options and RSUs awarded to new non-executive employees

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Key Terms

restricted stock unit, nasdaq listing rule 5635(c)(4), aldosterone synthase inhibitor

3 terms

restricted stock unit financial

"inducement restricted stock unit awards covering an aggregate of 22,320 shares"

A restricted stock unit is a promise from a company to give an employee shares of stock after certain conditions are met, like staying with the company for a set amount of time. It’s like earning a bonus that turns into company stock once you’ve proven your commitment, making it a way to motivate and reward employees.

nasdaq listing rule 5635(c)(4) regulatory

"in accordance with Nasdaq Listing Rule 5635(c)(4)"

NASDAQ Listing Rule 5635(c)(4) is a rule that requires a company to get approval from its shareholders before selling a large amount of its shares, usually over 20%. This helps protect investors by making sure the company doesn't flood the market with new shares without their say, which could lower the stock's value.

aldosterone synthase inhibitor medical

"a highly selective aldosterone synthase inhibitor"

Aldosterone synthase inhibitors are drugs that reduce production of the hormone aldosterone, which helps control salt, water balance, and blood pressure. Think of them as turning down a faucet that feeds excess blood pressure and fluid buildup; by lowering aldosterone they can ease strain on the heart and kidneys. Investors track these drugs because trial results, regulatory approval, and safety can materially affect a developer’s revenue outlook and stock value.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

RADNOR, Pa., Sept. 09, 2026 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (Nasdaq: MLYS), a biopharmaceutical company focused on developing medicines to target hypertension and aldosterone-related adverse outcomes in comorbid conditions such as chronic kidney disease, obstructive sleep apnea and other diseases driven by dysregulated aldosterone, announced today that, on September 8, 2026, the Compensation Committee of Mineralys’ Board of Directors granted inducement stock option awards covering an aggregate of 29,760 shares and inducement restricted stock unit awards covering an aggregate of 22,320 shares of Mineralys common stock to two new non-executive employees.

The awards were granted under Mineralys’ 2025 Employment Inducement Incentive Award Plan, which provides for the granting of equity awards to new employees of Mineralys. The option awards will vest over a four-year period, with 25% of the total shares underlying the options vesting on the first anniversary of the awards’ vesting commencement date, September 8, 2026, and 1/48th of the total shares underlying the options vesting following each one-month period thereafter, subject to continued service. The restricted stock unit awards will vest over a four-year period, with 25% of the shares vesting on each of the first four anniversaries of the awards’ vesting commencement date, September 8, 2026, subject to continued service. The awards were granted as an inducement material to the new non-executive employees entering into employment with Mineralys, in accordance with Nasdaq Listing Rule 5635(c)(4).

About Mineralys

Mineralys Therapeutics is a biopharmaceutical company focused on developing medicines to target hypertension and related comorbidities such as chronic kidney disease, obstructive sleep apnea and other diseases driven by dysregulated aldosterone. Its initial product candidate, lorundrostat, is an investigational, proprietary, orally administered, highly selective aldosterone synthase inhibitor. Mineralys is based in Radnor, Pennsylvania, and was founded by Catalys Pacific. For more information, please visit https://mineralystx.com. Follow Mineralys on LinkedIn, X and Bluesky.

Contact:

Investor Relations

investorrelations@mineralystx.com

Source: Mineralys Therapeutics, Inc.